Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-647-7 | CAS number: 1474044-68-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1963
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The study was conducted prior to the implementation of current testing guideline and GLP, however according to a still accepted testing method (Draize, 1944). Basic data were given and thus, the study is considered to be acceptable. The study was performed on an analogue substance (for justification of read-across, please refer to the corresponding assessment report in Section 13).
- Principles of method if other than guideline:
- The testing method was based on the Draize test as described in Draize et al. (1944), J Pharm and Exp Ther 82. Each of ten guinea pigs received a series of 10 injections of 0.1% test item solution, every other day, in a depilated skin region below the midline of the back. The first injected volume was 0.05 mL, the following injected volumes were 0.1 mL each. After 2 weeks following the last induction injection, challenge was conducted by injection of 0.05 mL of the test solution in the skin of the flank. The injection site was examined for skin reaction after a period of 24 hours following challenge.
- GLP compliance:
- no
- Type of study:
- Draize test
- Justification for non-LLNA method:
- Test in guinea pigs available before it was decided to register the substance.
- Specific details on test material used for the study:
- Form: Liquid
The study was performed on a commercial product (aqueous solution) as the test item is manufactured and used in a liquid form. - Species:
- guinea pig
- Strain:
- not specified
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: not specified
- Weight at study initiation: 350 - 450 g
- No further details provided - Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- 0.1%
- Day(s)/duration:
- 20 days, 10 injections
- Adequacy of induction:
- not specified
- No.:
- #1
- Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- 0.1%
- Day(s)/duration:
- 14 days after last induction
- Adequacy of challenge:
- not specified
- No. of animals per dose:
- 10
- Details on study design:
- A. INDUCTION EXPOSURE
- No. of exposures: 10
- Exposure period: 20 days
- Site: depilated skin region below the midline of the back
- Frequency of applications: injection was done every other day
- Concentrations: 0.1% test item solution
- Injected volume: 0.1 mL, except for the first injection (0.05 mL)
- Reading: skin readings were made at the injection sites, 24 hours after each injection had been done; the skin was examined for diameter, heigh and colour.
B. CHALLENGE EXPOSURE
- No. of exposures: one
- Challenge: done after 2 weeks following the last induction injection
- Site: skin of the flank.
- Concentrations: 0.1% test item solution
- Injected volume: 0.05 mL
- Evaluation (hr after challenge): 24 hours
READING
The application site was examined for diameter, heigh and colour. The readings were compared with those made at the sites of the first injection series (induction). If the reactions after challenge were appreciably more pronounced than those observed during induction, the test item was defined as a sensitizer. The degree of sensitization was considered to be, in part, proportional to the observed increase in skin reaction. - Reading:
- 1st reading
- Group:
- positive control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 0
- Remarks on result:
- not measured/tested
- Reading:
- 1st reading
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 0
- Total no. in group:
- 0
- Remarks on result:
- not measured/tested
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.1%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reaction at induction was characterized by a mean diameter of 3.6 mm, a mean height of < 1 mm, and a pink coloration (indicates slight erythema). Reaction after challenge had a mean diameter of 3.5 mm, a mean height of < 1mm, and a pink coloration.
- Remarks on result:
- no indication of skin sensitisation
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- CLP: not classified
DSD: not classified - Executive summary:
Sodium lauiminodipropionate, as a 10% aqueous solution, was tested at a concentration of 0.1% for sensitization according to the method of Draize (1944) using ten guinea pigs. Induction consisted of a series of 10 injections of 0.1 mL of test solution, except for the first injection done with 0.05 mL; the injections were done every other day over a period of 20 days. After 2 weeks following the last induction injection, challenge was done by single injection of 0.05 mL of the 0.1% test solution; skin reading was done after 24 hours.
Since no obvious differences were noticed when comparing the skin reaction at induction and that after challenge, sodium lauriminodipropionate was considered not to be a skin sensitizer unter the test conditions used.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Sodium lauriminodipropionate, as a 10% solution in water, was tested at a concentration of 0.1% for sensitization according to the method of Draize (1944) using ten guinea pigs. Since no obvious differences were observed when comparing the skin reaction at induction and that after challenge, the test substance was considered not to be a skin sensitizer under the test conditions used.
The reliability of these experimental results was considered sufficient to include this study as a key study for the present endpoint.
No valid information on respiratory sensitisation is available.
Migrated from Short description of key information:
Skin sensitisation:
- guinea-pig, Draize protocol (10% active ingredient), 0.1% induction (by injection): not sensitising, 0/10 positive (BASF, IBT 4451,1963)
Justification for selection of skin sensitisation endpoint:
Most reliable relevant study
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
- Migrated from Short description of key information:
Respiratory sensitisation:
-No data available
Justification for classification or non-classification
Skin sensitisation:
According to GHS and DSD criteria, substances shall be classified as skin sensitiser if there are positive results from appropriate animal tests. A skin sensitisation test with guinea pigs according to Draize protocol (BASF, IBT 4451,1963) showed no positive findings (0/10 tested animals) on a close analogue. Hence disodium cocoiminodipropionate needs not to be classified as sensitising to skin according to GHS (Regulation (EU) 1272/2008) or DSD (67/548/EEC).
Labelling for sensitisation:
GHS: no label
DSD: no label
Respiratory sensitisation:
No data available
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.